Grat Bio

Grat Bio is a China-based biotechnology company specializing in the development of next-generation gene therapies for central nervous system (CNS) disorders. The company utilizes a proprietary adeno-associated virus (AAV) platform to design treatments that address high unmet medical needs, with a primary focus on Parkinson's disease. Its lead candidate, GT-002, is an investigational gene therapy designed to restore dopamine production in the brain by delivering the AADC gene. Grat Bio aims to leverage its expertise in vector engineering and translational medicine to create long-lasting, transformative therapies for neurodegenerative conditions. The company is backed by prominent life science investors and is advancing multiple programs through pre-clinical development toward clinical trials.